Vomiting Clinical Trials

Orange : Call for Information (Investigational Site 0014)

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)

Palm Springs : Call for Information (Investigational Site 0021)

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Aurora : Call for Information (Investigational Site 0001)

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)

Washington : Call for Information (Investigational Site 0041)

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)

Hialeah : Call for Information (Investigational Site 0026)

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Jupiter : Call for Information (Investigational Site 0174)

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Lakeland : Call for Information (Investigational Site 0035)

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Miami : Call for Information (Investigational Site 0042)

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)

St. Petersburg : Call for Information (Investigational Site 0012)

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)

Anderson : Call for Information (Investigational Site 9277)

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Evansville : Call for Information (Investigational Site 0020)

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Indianapolis : Indiana University Melvin and Bren Simon Cancer Center

Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors

Cedar Rapids : Call for Information (Investigational Site 0037)

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Louisville : Call for Information (Investigational Site 0003)

A Study of Aprepitant (MK0869) in Pediatric Participants Undergoing Surgery (0869-148 AM1)

Baltimore : Call for Information (Investigational Site 0034)

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Rockville : Call for Information (Investigational Site 0036)

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Boston : Call for Information (Investigational Site 0020)

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)

Boston : Call for Information (Investigational Site 0013)

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)

Waltham : TESARO Inc

A Safety and Efficacy Study of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy

Waltham : TESARO Inc

A Safety and Efficacy Study of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderately Emetogenic Chemotherapy

Waltham : TESARO Inc

Phase 3 Safety and Efficacy Study of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy

View More »

Worcester : Call for Information (Investigational Site 0175)

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

St. Louis : Call for Information (Investigational Site 0043)

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)

Bronx : Children's Hospital at Montefiore

A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer

Durham : Duke University Medical Center

Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis

Philadelphia : University of Pennsylvania

Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain

Columbia : Call for Information (Investigational Site 0031)

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)

Nashville : Call for Information (Investigational Site 0022)

A Study of Aprepitant (MK0869) in Pediatric Participants Undergoing Surgery (0869-148 AM1)

Houston : Call for Information (Investigational Site 0176)

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Houston : UT MD Anderson Cancer Center

Fosaprepitant in Patients Receiving Ifosfamide-based Regimen

Temple : Scott and White Healthcare

Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients

Seattle : Call for Information (Investigational Site 0032)

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Spokane : Providence Sacred Heart Medical Center and Children's Hospital

Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years

Tacoma : Call for Information (Investigational Site 9315)

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Buenos Aires : Merck Sharp & Dohme (Argentina) Inc.

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)

Buenos Aires : Merck Sharp & Dohme (Argentina) Inc.

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Adelaide SA : RAH Cancer Centre, Royal Adelaide Hospital

Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin

South Granville : Merck Sharp & Dohme/Australia

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)

Vienna : Merck, Sharp & Dohme Ges.m.b.H.

Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Under 18 Years of Age (MK-0517-029 AM3)

Sao Paulo : MSD

A Study of Aprepitant (MK0869) in Pediatric Participants Undergoing Surgery (0869-148 AM1)

Sao Paulo : MSD

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)

Sofia : Merck Sharp & Dohme Bulgaria EOOD

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Kirkland : Merck Frosst Canada Ltd.

Fosaprepitant (EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030 AM1)

Santiago : Merck Sharp & Dohme (I.A.) Corp.

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)

Bogota : MDS Colombia SAS

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)

Bogota : MDS Colombia SAS

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Praha : Merck Sharp and Dohme s.r.o.

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Aarhus : Department of Oncology

Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin

Copenhagen : Rigshospitalet, Finsen Centret

Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin

Glostrup : Merck Sharp & Dohme

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)

Herlev : Herlev Hospital

Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin

Odense : Department of Oncology, Odense University Hospital

Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin

Santo Domingo : MSD CARD

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)

Quito : MSD Ecuador

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)

Espoo : MSD Finland Oy

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Courbevoie : Laboratoires Merck Sharp & Dohme - Chibret

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)

Berlin : Vivantes Klinikum Neukolln

Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin

Haar : MSD Sharp & Dohme GMBH

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)

Haar : MSD Sharp & Dohme GMBH

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Kiel : Universitatsklinikum Schleswig Holstein

Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin

Alimos : Vianex, S.A. / MSD

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)

Alimos : Vianex, S.A. / MSD

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Budapest : MSD Pharma Hungary Kft.

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)

Budapest : MSD Pharma Hungary Kft.

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Budapest : MSD Pharma Hungary Kft.

Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Under 18 Years of Age (MK-0517-029 AM3)

New Delhi : Dr. BRA IRCH, AIIMS

Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy

Hod Hasharon : Merck Sharp & Dohme Co. Ltd.

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)

Hod Hasharon : Merck Sharp & Dohme Co. Ltd.

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)

Milan : MSD Italia S.r.l..

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)

Milan : MSD Italia

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Hidaka : Research site

Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)

Kashihara : Research site

Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)

Kashiwa : Research site

Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)

Koshigaya : Research Site

Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)

Kyoto : Research

Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)

View More »

Maebashi : Research site

Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)

Nagoya : Research site

Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)

Nakagami : Research site

Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)

Niigata : Research site

Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)

Ota : Research site

Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)

Sagamihara : Research site

Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)

Sapporo : Research site

Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)

Sayama : Research site

Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)

Tokyo : Reseach site

Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)

Tokyo : Research site

Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)

Yamagata : Research site

Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)

Yokohama : Research site

Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)

Seoul : MSD Korea Ltd.

A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225 AM1) (KMEC)

Seoul : Seoul St. Mary's Hospital

Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in Chemotherapy-induced Nausea and Vomiting Associated With the Administration of Highly Emetogenic Chemotherapy (HEC)

Seoul : Samsung Medical Center

Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in CINV (Chemotherapy-induced Nausea and Vomiting) Associated With the Administration of MEC (Moderately Emetogenic Chemotherapy)

Seoul : Kangpook Samsung Hospital

Therapeutic Efficacy and Safety of Palonosetron in Treatment of Postoperative Nausea and Vomiting

Seoul : Sangye Bahk Hospital, Inje School of Medicine

Therapeutic Efficacy and Safety of Palonosetron in Treatment of Postoperative Nausea and Vomiting

View More »

Seoul : Bungdang Seoul National University Hospital

Therapeutic Efficacy and Safety of Palonosetron in Treatment of Postoperative Nausea and Vomiting

Seoul : Samsung Medical Center

Therapeutic Efficacy and Safety of Palonosetron in Treatment of Postoperative Nausea and Vomiting

Riga : Merck Sharp & Dohme Latvija SIA

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Vilnius : UAB "Merck Sharp & Dohme"

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)

Mexico City : MSD

A Study of Aprepitant (MK0869) in Pediatric Participants Undergoing Surgery (0869-148 AM1)

Mexico City : MSD

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)

Mexico City : MSD

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)

Haarlem : Merck Sharp & Dohme BV

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)

Haarlem : Merck Sharp & Dohme BV

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Drammen : MSD (Norge) AS

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)

Drammen : MSD (Norge) AS

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Oslo : The Norwegian Radium Hospital

Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin

Lima : Merck Sharp & Dohme, Peru S.R.L.

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)

Lima : Merck Sharp & Dohme, Peru S.R.L.

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)

Lima : Merck Sharp & Dohme, Peru S.R.L.

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Warszawa : MSD Polska Sp. Z o.o.

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)

Warszawa : MSD Polska Sp. Z o.o.

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)

Warszawa : MSD Polska Sp. Z o.o.

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Paco D`arcos : Merck Sharp & Dohme Lda.

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Paco D`arcos : Merck Sharp & Dohme Lda.

Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Under 18 Years of Age (MK-0517-029 AM3)

Moscow : Merck Sharp & Dohme IDEA, Inc.

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)

Ljubljana : Merck Sharp & Dohme Idea, Inc

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)

Madrid : Merck Sharp and Dohme de Espana S.A.

A Study of Aprepitant (MK0869) in Pediatric Participants Undergoing Surgery (0869-148 AM1)

Madrid : Merck Sharp and Dohme de Espana S.A.

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)

Madrid : Merck Sharp and Dohme de Espana S.A.

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)

Madrid : Merck Sharp and Dohme de Espana S.A.

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Madrid : Merck Sharp and Dohme de Espana S.A.

Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Under 18 Years of Age (MK-0517-029 AM3)

Sollentuna : MSD

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)

Sollentuna : MSD

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)

Sollentuna : MSD

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Glattbrugg : MSD Merck Sharp & Dohme AG

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)

Bangkok : MSD (Thailand) Ltd.

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)

Istanbul : Merck Sharp & Dohme Ilaclari Ltd. Sti

A Study of Aprepitant (MK0869) in Pediatric Participants Undergoing Surgery (0869-148 AM1)

Istanbul : Merck Sharp & Dohme Ilaclari Ltd. Sti

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)

Hoddesdon : Merck Sharp & Dohme Ltd.

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)